Concepedia

Bernard M. Tijink

BM

13

Publications

1.3K

Citations

13

H-Index

2005

Active since

Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam(Current)

University Medical Center Utrecht

The Netherlands Cancer Institute

Bayer (Germany)

Palmetto Hematology Oncology

Bernard M. Tijink is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, engineering, and dermatology.

ORCID

Top concepts

Publications per year

2005–2022

13

Publications

13

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Bernard M. Tijink, Jan Buter, Remco de Bree et al. · Clinical Cancer Research · 2006 · 310 citations · Full text

Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

Bernard M. Tijink, Toon Laeremans, Marianne Budde et al. · Molecular Cancer Therapeutics · 2008 · 289 citations

, , +21

(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Lars R. Perk, Gerard W.M. Visser, Maria J.W.D. Vosjan et al. · PubMed · 2005 · 205 citations

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Bernard M. Tijink, Dario Neri, C. René Leemans et al. · PubMed · 2006 · 104 citations

124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

Bernard M. Tijink, Lars R. Perk, Marianne Budde et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 101 citations · Full text

Rows per page

1–5 of 13